PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview

Islam Kourampi; Ioannis-Panagiotis Tsetzan; Panagiota Kappi; Nityanand Jain

doi:10.3390/uro3010006

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview

Islam Kourampi (Corresponding Author), Ioannis-Panagiotis Tsetzan, Panagiota Kappi, Nityanand Jain (Corresponding Author)

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

15 Downloads (Pure)

Abstract

Prostate cancer is the second most common form of cancer in men and the fifth leading cause of death among men worldwide. Men with metastatic castration-resistant prostate cancer (mCRPC) often have BRCA-1 or BRCA-2 gene mutations which can make them sensitive to poly-(ADP-ribose) polymerase inhibitors or PARP inhibitors (PARPi), such as Olaparib, Rucaparib, and Niraparib. Although significant advances have been made with PARPi and the prognosis of patients with mCRPC has improved dramatically, resistance often constitutes a challenge that frequently results in tumor escape. This present communication paper explores the role of PARPi in BRCA-positive prostate cancer and sheds light on numerous published and ongoing clinical trials that will determine the future of PARPi at various tumor stages as a monotherapy or polytherapy regime.

Original language	English
Pages (from-to)	40-47
Number of pages	8
Journal	Uro
Volume	3
Issue number	1
DOIs	https://doi.org/10.3390/uro3010006
Publication status	Published - 19 Jan 2023

Keywords*

prostate cancer
Parpi
BRCA
inhibitors
treatment
resistance

Field of Science*

3.2 Clinical medicine

Publication Type*

1.4. Reviewed scientific article published in Latvia or abroad in a scientific journal with an editorial board (including university editions)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/uro3010006Licence: CC BY

PARP Inhobitors in the management of BRCAFinal published version, 444 KBLicence: CC BY

https://www.mdpi.com/2673-4397/3/1/6?fbclid=IwAR2lweYODQHTy0IYiSCK85G17lppkct-0HYVxhcxmXpsnA7lcfBXtEIBWMcLicence: CC BY

Cite this

@article{621552b0144b4e91abc5177b246d54f1,

title = "PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview",

abstract = "Prostate cancer is the second most common form of cancer in men and the fifth leading cause of death among men worldwide. Men with metastatic castration-resistant prostate cancer (mCRPC) often have BRCA-1 or BRCA-2 gene mutations which can make them sensitive to poly-(ADP-ribose) polymerase inhibitors or PARP inhibitors (PARPi), such as Olaparib, Rucaparib, and Niraparib. Although significant advances have been made with PARPi and the prognosis of patients with mCRPC has improved dramatically, resistance often constitutes a challenge that frequently results in tumor escape. This present communication paper explores the role of PARPi in BRCA-positive prostate cancer and sheds light on numerous published and ongoing clinical trials that will determine the future of PARPi at various tumor stages as a monotherapy or polytherapy regime.",

keywords = "prostate cancer, Parpi, BRCA, inhibitors, treatment, resistance",

author = "Islam Kourampi and Ioannis-Panagiotis Tsetzan and Panagiota Kappi and Nityanand Jain",

year = "2023",

month = jan,

day = "19",

doi = "10.3390/uro3010006",

language = "English",

volume = "3",

pages = "40--47",

journal = "Uro",

issn = "2673-4397",

publisher = "MDPI Multidisciplinary Digital Publishing Institute",

number = "1",

}

TY - JOUR

T1 - PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview

AU - Kourampi, Islam

AU - Tsetzan, Ioannis-Panagiotis

AU - Kappi, Panagiota

AU - Jain, Nityanand

PY - 2023/1/19

Y1 - 2023/1/19

N2 - Prostate cancer is the second most common form of cancer in men and the fifth leading cause of death among men worldwide. Men with metastatic castration-resistant prostate cancer (mCRPC) often have BRCA-1 or BRCA-2 gene mutations which can make them sensitive to poly-(ADP-ribose) polymerase inhibitors or PARP inhibitors (PARPi), such as Olaparib, Rucaparib, and Niraparib. Although significant advances have been made with PARPi and the prognosis of patients with mCRPC has improved dramatically, resistance often constitutes a challenge that frequently results in tumor escape. This present communication paper explores the role of PARPi in BRCA-positive prostate cancer and sheds light on numerous published and ongoing clinical trials that will determine the future of PARPi at various tumor stages as a monotherapy or polytherapy regime.

AB - Prostate cancer is the second most common form of cancer in men and the fifth leading cause of death among men worldwide. Men with metastatic castration-resistant prostate cancer (mCRPC) often have BRCA-1 or BRCA-2 gene mutations which can make them sensitive to poly-(ADP-ribose) polymerase inhibitors or PARP inhibitors (PARPi), such as Olaparib, Rucaparib, and Niraparib. Although significant advances have been made with PARPi and the prognosis of patients with mCRPC has improved dramatically, resistance often constitutes a challenge that frequently results in tumor escape. This present communication paper explores the role of PARPi in BRCA-positive prostate cancer and sheds light on numerous published and ongoing clinical trials that will determine the future of PARPi at various tumor stages as a monotherapy or polytherapy regime.

KW - prostate cancer

KW - Parpi

KW - BRCA

KW - inhibitors

KW - treatment

KW - resistance

UR - https://www.mendeley.com/catalogue/b1525c12-2cee-3c99-b046-b7736ec09b00/

U2 - 10.3390/uro3010006

DO - 10.3390/uro3010006

M3 - Article

SN - 2673-4397

VL - 3

SP - 40

EP - 47

JO - Uro

JF - Uro

IS - 1

ER -

PARP Inhibitors in the Management of BRCA-Positive Prostate Cancer: An Overview

Abstract

Keywords*

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this